When this happens, I firstly suspect that the spacegroup may be wrong. We had a case where the symmetry was pseudo I4212 but was really I222 (or was it really I212121) Anyway most of the structure obeyed the I41212 symmetry but there was a tail which did not..)

Feed the unmerged reflections into pointless and see what it suggests

Eleanor

Zhou, Tongqing (NIH/VRC) [E] wrote:
Hi Everyone,

I have some problem in refining a structure. The data goes to 2.4A (with some 
30% completeness at 2.15A), the structure was solved by MR with Phaser, 
refinement was done with Phenix, but the r and r-free are now staying at 26% 
and 32%, even with all possible waters and missing fragments added. Data was 
collected at APS at cryo condition. One thing I noticed during HKL2000 data 
processing was that the chi^2 were way too high at lower resolutions shells,  I 
had to adjust the default error model in HKL2000 to get the chi^2 to around 1, 
but this adjustment reduced the overall I/sigI ratio a lot (from around 20 to 
5).

The quality of electron density maps looks fine to me for a 2.4 A data set and 
I was able to build all the missing CDR loops for the antibody in the complex. 
I am lost now, should I just re-collect a new data set?

Thanks,


Tongqing

Tongqing Zhou, Ph.D.
Staff Scientist
Structural Biology Section
Vaccine Research Center, NIAID/NIH
Building 40, Room 4607B
40 Convent Drive, MSC3027
Bethesda, MD 20892
(301) 594-8710 (Tel)
(301) 793-0794 (Cell)
(301) 480-2658 (Fax)
******************************************************************
The information in this e-mail and any of its attachments is confidential and 
may contain sensitive information. It should not be used by anyone who is not 
the original intended recipient. If you have received this e-mail in error 
please inform the sender and delete it from your mailbox or any other storage 
devices. National Institute of Allergy and Infectious Diseases shall not accept 
liability for any statements made that are sender's own and not expressly made 
on behalf of the NIAID by one of its representatives.
******************************************************************


Reply via email to